Public Market Listing
1672 HKEX
HKEX primary exchange listing
External market data link · No third-party exchange redistribution
Assets (4 total) 4 Total Assets
0 Approved
3 Phase 3 / Filed
1 Phase 1–2 / Early
8 Diseases
Disease: All diseases (4) Obesity (2) Type 2 Diabetes (1) MASH / NASH (1) Glioblastoma (1) HIV (1) Non-Small Cell Lung Cancer (1) Chronic Hepatitis B (1) Endometrial Cancer (1)
Stage: All stages (4) Approved / Phase 4 (0) Phase 3 / Filed (3) Phase 2 Phase 1 / Preclinical
Quick filter: All (4) Obesity (2) Type 2 Diabetes (1) MASH / NASH (1) Glioblastoma (1) HIV (1)
Showing 4 of 4 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 GLP-1 receptor Small molecule
Phase 3 Fatty acid synthase (FASN) · FASN Small molecule
MASH / NASH Glioblastoma
Recurrent Glioblastoma Phase 3 PD-L1 Monoclonal antibody
HIV Non-Small Cell Lung Cancer Chronic Hepatitis B Endometrial Cancer
Phase 1 Thyroid hormone receptor-beta Small molecule
Upcoming events (8 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (2) December 2026 (2) Envafolimab Phase 1/2 Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma Est. primary completion 2026-12 ·
NCT05024214 ·
CT.gov ↗ What to watch
Envafolimab Phase 2 Advanced Endometrial Cancer Est. primary completion 2026-12 ·
NCT05112991 ·
CT.gov ↗ What to watch
2027 (3) August 2027 (2) Denifanstat Phase 3 Acne Vulgaris Est. primary completion 2027-08 ·
NCT07863193 ·
CT.gov ↗ What to watch
Envafolimab Phase 2 Solid Tumor Est. primary completion 2027-08-30 ·
NCT04891198 ·
CT.gov ↗ What to watch
December 2027 (1) Envafolimab Phase 3 Non-small Cell Lung Cancer Est. primary completion 2027-12-30 ·
NCT06123754 ·
CT.gov ↗ What to watch
2028 (2) July 2028 (2) ASC30 Phase 3 Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus Est. primary completion 2028-07 ·
NCT07743450 ·
CT.gov ↗ What to watch
ASC30 Phase 3 Obesity, Overweight, Chronic Weight Management Est. primary completion 2028-07 ·
NCT07743463 ·
CT.gov ↗ What to watch
2029 (1) June 2029 (1) Envafolimab Phase 2 Biliary Tract Neoplasms Est. primary completion 2029-06 ·
NCT04910386 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (2) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
10 December 2025 Filing accepted Denifanstat NMPA accepts denifanstat acne NDA 4 June 2025 Topline result Denifanstat China phase III acne topline Financial reports Annual history (2 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $0.3M $57M $206M $50M report ↗
View 1 more year Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $0.2M $42M $118M $42M report ↗